PDF(Pubmed)
Abstract：
Eribulin is a non-taxane synthetic analogue approved in many countries as third-line treatment for the treatment of patients with metastatic breast cancer. In addition to its mitotic property, eribulin has non-mitotic properties including but not limited to, its ability to induce phenotypic reversal of epithelial to mesenchymal transition, vascular remodelling, reduction in immunosuppressive tumour microenvironment. Since approval, there has been a surge in studies investigating the application of eribulin as an earlier-line treatment and also in combination with other agents such as immunotherapy and targeted therapy across all breast cancer sub-types, including hormone receptor positive, HER2 positive and triple negative breast cancer, many demonstrating promising activity. This review will focus on the application of eribulin in the treatment of metastatic breast cancer across all subtypes including its role as an earlier-line agent, its toxicity profile, and potential future directions.
摘要：
Eribulin是一种非紫杉烷合成类似物，在许多国家被批准作为治疗转移性乳腺癌患者的三线治疗方法。除了其有丝分裂性质，艾瑞布林具有非有丝分裂特性，包括但不限于，它能够诱导上皮向间充质转化的表型逆转，血管重塑,减少免疫抑制肿瘤微环境。自批准以来，在所有乳腺癌亚型中，有大量的研究调查了艾日布林作为早期治疗的应用，以及与其他药物如免疫疗法和靶向治疗的联合应用，包括激素受体阳性,HER2阳性和三阴性乳腺癌，许多展示有希望的活动。本文将重点介绍艾瑞布林在所有亚型转移性乳腺癌治疗中的应用，包括其作为早期药物的作用。它的毒性特征，和潜在的未来方向。
